SynthesisFrontiers in microbiology2026
Mapping research trends in irritable bowel syndrome and the gut microbiome: a cross-database bibliometric analysis.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Research on irritable bowel syndrome (IBS) and the gut microbiome has expanded rapidly. However, the structural evolution of this literature has not been systematically characterized across major indexing platforms. Methods: We performed a parallel bibliometric analysis of the Web of Science Core Collection (WoSCC, Results: Annual output increased from fewer than 10 articles per year before 2010 to 162 in 2025. This acceleration became marked after 2014 and was reproduced across all three databases. The United States and China led publication volume, whereas the UK output was concentrated in a small number of flagship centers. Our analysis suggests three developmental phases: compositional profiling and culture-dependent benchmarks (2000-2012), community-level characterization and interventional consolidation (2012-2017), and neuroendocrine and short-chain fatty acid mechanisms (2017-2025). Visceral hyperalgesia and hypothalamic-pituitary-adrenal axis dysregulation showed the strongest currently active keyword bursts. Diet-related and precision-oriented approaches also gained visibility. Conclusion: IBS-gut microbiome research has shifted from descriptive profiling toward mechanistic, diet-related, and precision-medicine themes. These findings provide a structured overview of the field and help clarify priorities for its next phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.